Clinical Research Directory

A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control

This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite, satiety, and energy levels in overweight and obese adults over six weeks. A total of 170 generally healthy adults aged 18-65 years with a BMI of 27.0-35.0 kg/m² will be randomized 1:1 to receive either the active supplement or a matching placebo. Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform. The primary outcome is change in body weight from Baseline to Week 6.

High-Dairy Food Patterns and Gut-Brain Axis

Disturbances in brain insulin sensitivity are associated not only with obesity and type 2 diabetes, but also with brain aging and cognitive decline. Longitudinal studies suggest that dietary patterns, particularly those high in dairy intake, may impact brain function via the gut-brain axis. Indeed, dairy foods are known to modulate gut microbiota and may, through this pathway, not only improve brain insulin sensitivity and cognitive performance, but also mental health and appetite regulation. However, underlying mechanisms remain largely unexplored. The primary objective of this study is to evaluate, in older adults with overweight or obesity, the effects of a high-dairy food pattern (4-5 daily servings of (butter)milk, cheese, yogurt, or cottage cheese) compared to a low-dairy food pattern (≤1 serving daily) on (regional) brain vascular function and insulin sensitivity. These outcomes will be quantified using the non-invasive MRI perfusion technique Arterial Spin Labeling (ASL), which assesses cerebral blood flow (CBF) in response to intranasal insulin, a validated physiological marker of brain insulin sensitivity. Secondary objectives include changes in cognitive performance (via the CANTAB neuropsychological test battery), gut microbiota composition (via shotgun metagenomic analysis of fecal samples), and appetite-related brain reward activity (via BOLD-fMRI with food cues). Exploratory analyses include conventional cardiometabolic risk markers (blood pressure, lipid and glucose metabolism), and perceivable (consumer) benefits.